Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II -: Mediated vasoconstriction

被引:35
作者
Giebing, G
Tölle, M
Jürgensen, J
Eichhorst, J
Furkert, J
Beyermann, M
Neuschäfer-Rube, F
Rosenthal, W
Zidek, W
van der Giet, M
Oksche, A
机构
[1] Charite, Med Klin Nephrol 4, D-12200 Berlin, Germany
[2] Charite, Inst Pharmakol, Berlin, Germany
[3] Forschungsinst Mol Pharmakol, Berlin, Germany
[4] Univ Potsdam, Inst Ernahrungswissensch, Nuthetal, Germany
关键词
urotensin II; vascular tone; urotensin receptor; recycling; internalization;
D O I
10.1161/01.RES.0000184670.58688.9F
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Urotensin II (UII), which acts on the G protein-coupled urotensin ( UT) receptor, elicits long-lasting vasoconstriction. The role of UT receptor internalization and intracellular trafficking in vasoconstriction has yet not been analyzed. Therefore, UII-mediated contractile responses of aortic ring preparations in wire myography and rat UT (rUT) receptor internalization and intracellular trafficking in binding and imaging analyses were compared. UII elicited a concentration-dependent vasoconstriction of rat aorta (-log EC50, mol/L:9.0 +/- 0.1). A second application of UII after 30 minutes elicited a reduced contraction (36 +/- 4% of the initial response), but when applied after 60 minutes elicited a full contraction. In internalization experiments with radioactive labeled VII (I-125-UII), approximate to 70% of rUT receptors expressed on the cell surface of human embryonic kidney 293 cells were sequestered within 30 minutes (half life [t(h)]: 5.6 +/- 0.2 minutes), but recycled quantitatively within 60 minutes (t(h) 31.9 +/- 2.6 minutes). UII-bound rUT receptors were sorted to early and recycling endosomes, as evidenced by colocalization of rUT receptors with the early endosomal antigen and the transferrin receptor. Real-time imaging with a newly developed fluorescent UII (Cy3-UII) revealed that rUT receptors recruited arrestin3 green fluorescent protein to the plasma membrane. Arrestin3 was not required for the endocytosis of the rUT receptor, however, as internalization of Cy3-UII was not altered in mouse embryonic fibroblasts lacking endogenous arrestin2/arrestin3 expression. The data demonstrate that the rUT receptor internalizes arrestin independently and recycles quantitatively. The continuous externalization of rUT receptors provides the basis for repetitive and lasting UII-mediated vasoconstriction.
引用
收藏
页码:707 / 715
页数:9
相关论文
共 41 条
[1]   No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans [J].
Affolter, JT ;
Newby, DE ;
Wilkinson, IB ;
Winter, MJ ;
Balment, RJ ;
Webb, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (06) :617-621
[2]   Cloning and pharmacological characterization of the cat urotensin-II receptor (UT) [J].
Aiyar, N ;
Johns, DG ;
Ao, ZH ;
Disa, J ;
Behm, DJ ;
Foley, JJ ;
Buckley, PT ;
Sarau, HM ;
van-der-Keyl, HK ;
Elshourbagy, NA ;
Douglas, SA .
BIOCHEMICAL PHARMACOLOGY, 2005, 69 (07) :1069-1079
[3]   Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J].
Ames, RS ;
Sarau, HM ;
Chambers, JK ;
Willette, RN ;
Alyar, NV ;
Romanic, AM ;
Louden, CS ;
Foley, JJ ;
Sauermelch, CF ;
Coatney, RW ;
Ao, ZH ;
Disa, J ;
Holmes, SD ;
Stadel, JM ;
Martin, JD ;
Liu, WS ;
Glover, GI ;
Wilson, S ;
McNulty, DE ;
Ellis, CE ;
Elshourbagy, NA ;
Shabon, U ;
Trill, JJ ;
Hay, DWP ;
Ohlstein, EH ;
Bergsma, DJ ;
Douglas, SA .
NATURE, 1999, 401 (6750) :282-286
[4]   GPCR interacting proteins (GIP) [J].
Bockaert, J ;
Fagni, L ;
Dumuis, A ;
Marin, P .
PHARMACOLOGY & THERAPEUTICS, 2004, 103 (03) :203-221
[5]   Urotensin II evokes potent vasoconstriction in humans in vivo [J].
Böhm, F ;
Pernow, J .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (01) :25-27
[6]   Effects of human urotensin II in isolated vessels of various species;: comparison with other vasoactive agents [J].
Camarda, V ;
Rizzi, A ;
Calò, G ;
Gendron, G ;
Perron, SI ;
Kostenis, E ;
Zamboni, P ;
Mascoli, F ;
Regoli, D .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 (02) :141-149
[7]   Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt):: First demonstration of a pathophysiological role of the urotensin system [J].
Clozel, M ;
Binkert, C ;
Birker-Robaczewska, M ;
Boukhadra, C ;
Ding, SS ;
Fischli, W ;
Hess, P ;
Mathys, B ;
Morrison, K ;
Müller, C ;
Müller, C ;
Nayler, O ;
Qiu, CB ;
Rey, M ;
Scherz, MW ;
Velker, J ;
Weller, T ;
Xi, JF ;
Ziltener, P .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 311 (01) :204-212
[8]   Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? [J].
Douglas, SA .
CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (02) :159-167
[9]   Congestive heart failure and expression of myocardial urotensin II [J].
Douglas, SA ;
Tayara, L ;
Ohlstein, EH ;
Halawa, N ;
Giaid, A .
LANCET, 2002, 359 (9322) :1990-1997
[10]   Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease [J].
Douglas, SA ;
Ohlstein, EH .
TRENDS IN CARDIOVASCULAR MEDICINE, 2000, 10 (06) :229-237